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1. Introduction 
Malaria (Plasmodium falciparum) infects 200 to 300 million people globally and kills 
900,000 (mostly children) every year. Severe malaria-related pathogeneses impacts a 
broad spectrum of host system and multiple organs (Zhu, Wu et al. 2009). Up to 20% of 
fatal cases are due to cerebral malaria (CM) and other severe forms of malaria such as 
severe malaria anemia (SMA). The precise mechanisms responsible for fatal CM-induced 
brain damage are unclear. To date, two main hypotheses have been proposed for human 
cerebral malaria. The first is the mechanical hypothesis, which proposes that infected or 
parasitized red blood cells (iRBC, or pRBC) bind to endothelial cells (EC), thus 
obstructing blood flow in micro capillaries leading to low tissue perfusion, compromised 
oxygenation and tissue damage. The second is the immunopathological hypothesis 
which proposes that hyper-inflammatory responses responsible for eliminating P. 
falciparum parasite cause edema, dysfunction in blood brain barrier (BBB), and organ 
failure and death.  
Current anti-malaria drugs, such as quinine and artemisinin derivatives can effectively clear 
the parasites in blood, however a significant segment of severe malaria patients including 
CM patients still die or develop severe sequelae regardless of treatment (Taoufiq, Gay et al. 
2008; Balachandar and Katyal 2010). Therefore important questions remain to be answered 
concerning the mechanism/(s) governing CM pathogenesis and appropriate therapies. The 
existing anti-malaria therapies are not sufficient partly due to drug resistance and various 
side effects, but beyond that these treatments mainly focus on the clearance of parasite, a 
direct antiplasmodial strategy, and are unable to prevent secondary changes such as 
encephalopathy resulting from parasite derived factors. The molecular mechanisms 
involved in malaria pathogenesis are highly complex and multifactorial. Recent studies have 
demonstrated that many pathological changes result from malaria-induced secondary 
effects involving various signaling molecules of the host (Armah, Wilson et al. 2007; 
Pamplona, Ferreira et al. 2007; Pamplona, Hanscheid et al. 2009). A better understanding of 
malaria host-parasite interactions will facilitate the development of novel strategies for 
intervention. 
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2. Pathological abnormalities associated with CM 
2.1 Histopathologic hallmarks of the CM 
The histopathologic hallmark of CM is sequestration of infected red blood cells in the 
microcirculation of the brain and retina (White 2011). A study performed in South Asia to 
quantitatively analyze the microvascular sequestration of P. falciparum in human brain 
demonstrated that sequestration occurs in all patients with falciparum malaria and is a 
consistent characteristic of severe malaria (Silamut, Phu et al. 1999). Fibrin thrombi and 
perivascular ring hemorrhages are also frequently found intravascular and extravascular. 
Diffuse petechial hemorrhages are seen in the cerebrum and cerebellum (Patankar, Karnad 
et al. 2002). Red blood cells (RBCs) around capillaries with hemorrhages are usually non-
infected, because parasitized RBCs (pRBCs) are adherent to the endothelial cells in the 
vessel walls and are unable to freely bleed into the parenchyma (sequestration theory) 
(White 2011). Patches of necrosis are present around vessels with thrombi, with or without 
hemorrhages. Inflammation in the parenchyma of the brain or retina is not significant. Anti-
malaria therapy could effectively eliminate parasites from the brains, but such interventions 
cannot always reverse malaria-induced primary or secondary pathological processes in 
severely diseased individuals. Circulating pRBCs will sequester as they mature (schizonts 
and trophozoites) (Silamut, Phu et al. 1999; Rogerson, Grau et al. 2004), but it is unclear 
what determines adherence to sites where severe pathology is common in the brain 
compared to sites where consequences appear minor such as in gastrointestinal tract and 
skin (Rogerson, Grau et al. 2004). Histopathological studies from animal models have also 
indicated that experimental cerebral malaria (ECM) is associated with microvascular 
plugging (sequestration of pRBCs, leukocytes and platelets), blood brain barrier (BBB) 
compromise, parenchymal petechial hemorrhages and edema (Medana, Chaudhri et al. 
2001; Penet, Viola et al. 2005). Histology is the least expensive morphological technique, 
which enables examination of large areas of tissue, but all the lesions described above are 
not specific for malaria. 
2.2 Retinal changes associated with CM 
A postmortem study from Taylor et al (Taylor, Fu et al. 2004) raised an important question 
of how to accurately diagnose cerebral malaria. They found that one quarter of patients 
clinically diagnosed as cerebral malaria had an alternative cause of death, with no 
histopathologic findings typical of cerebral malaria. The retinal and cerebral circulations 
share a common embryologic origin, therefore changes identified by ophthalmoscopy at the 
fundus could be very helpful to accurately diagnose cerebral malaria (White, Lewallen et al. 
2009; Beare, Lewallen et al. 2011). To this end, a case-control study was conducted during 
1996 to 2008 in Malawi to analyze the differences in clinical and/or pathological alterations 
between children dying from CM and those dying of other deadly infectious diseases (White 
2011). This project [supported by the National Institutes of Health (NIH) and named the 
Blantyre Malaria Project (BMP)] emphasized the application of the fundus as a tool to help 
diagnosis and prognosis for CM. All of the CM patients were asked to receive a full 
examination of eyes. At the end of 2008, 90 autopsies were performed among 352 deceased 
individuals. The patients’ eyes were also removed for pathological analysis and 
clinicopathological correlation. Through this project, a clinicopathologic correlation of 
retinal hemorrhages with brain bleeding was substantially established, and they established 
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the diagnostic criteria for malaria retinopathy based on their findings of retinal hemorrhages 
as well as three other pathological changes (White 2011), papilledema, an unusual 
discoloration of the retinal vessels, and a patchy whitening of the retina surrounding the 
fovea and in the periphery (White 2011). Today, malarial retinopathy is widely accepted as a 
diagnostic and prognostic factor in human cerebral malaria (White, Lewallen et al. 2009; 
Combes, El-Assaad et al. 2010). It has been strongly recommended that retina examination 
become a routine technique to assess a comatose child or adult when CM is a possible 
diagnosis (Beare, Lewallen et al. 2011). However, a key limitation of the retinal assessment is 
the subjective nature of ophthalomoscopy and its dependence on the expertise of the 
examining physician.  
2.3 Magnetic resonance imaging 
The first in vivo magnetic resonance on experimental CM was performed by Penet et al in 
2005 (Penet, Viola et al. 2005). Magnetic resonance imaging (MRI) and magnetic resonance 
spectroscopy (MRS) are noninvasive and quantitative techniques which can identify not 
only structural but also functional and metabolic changes in experimental CM. They have 
confirmed characteristics of severe brain edema, parechymal tissue damage, cerebral 
hemorrhages, BBB disruption (Penet, Viola et al. 2005), and reduced cerebral blood flow in 
ECM (Penet, Viola et al. 2005). The hemorrhages mostly occurred in the corpus callosum. 
Crushing of the cerebellum and the pituitary gland, distortion of the brain stem and 
cerebellum are also frequently observed. These noninvasive and quantitative techniques will 
be as promising as surrogate tools used to monitor the progression of malaria and the 
efficacy of anti-malaria treatments (Penet, Viola et al. 2005; Vyas, Gupta et al. 2010; Rasalkar, 
Paunipagar et al. 2011). The BMP project (see 2.2) is conducting a magnetic resonance 
imaging scan to assess association between the brains of living individuals and prognosis of 
CM (White 2011). However, MRI systems are very expensive, emphasize the need to 
consider strategies that most severe malaria patients who are from underdeveloped African 
countries could afford. 
3. Functional abnormalities commonly associated with CM 
Cognitive impairment. CM in children is not only related to high mortality but also long-term 
neurocognitive sequelae (Casals-Pascual, Idro et al. 2008). Children with CM developed new 
neurological deficits such as gross motor, sensory, and language problems significantly 
more than corresponding controls (Birbeck, Molyneux et al. 2010). Many children with 
severe malaria suffer from intracranial hypertension caused by brain endothelial injury, 
apoptosis, and BBB dysfunction (Idro, Marsh et al. 2010). Intracranial hypertension 
compromises brain perfusion, nutrient and oxygen delivery leading to global ischemic 
injury, herniation, brainstem compression, and death (Walker, Salako et al. 1992; Newton, 
Crawley et al. 1997). Many children with severe malaria are discharged with spastic 
quadriplegia and severe learning disability (Newton, Crawley et al. 1997). Even if the gross 
neurological function can be almost completely recovered, hypoxia due to under-perfusion 
in multiple small areas still leaves many children with cognitive deficiencies (Idro, Marsh et 
al. 2010). In several retrospective and prospective studies, cognitive dysfunction in children 
with CM have been found to occur more frequently, and persist far longer than physical and 
neurologic deficits (Dugbartey, Spellacy et al. 1998; Holding, Stevenson et al. 1999; Carter, 
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Mung'ala-Odera et al. 2005; Carter, Lees et al. 2006; Boivin, Bangirana et al. 2007; John, 
Bangirana et al. 2008). 11.8% of surviving children had deficits particularly in vocabulary, 
receptive and expressive speech, word finding and phonology, concomitant with concurrent 
impairment in nonverbal functioning, memory or attention (Carter, Lees et al. 2006). The 
duration of seizures and extended comas are related to persistent cognitive deficits (Boivin, 
Bangirana et al. 2007). 
Coma. Marsh et al (Marsh, English et al. 1996; Idro, Marsh et al. 2010) divided CM into four 
distinct groups based on the severity of neurological dysfunction (Marsh, English et al. 1996; 
Idro, Marsh et al. 2010). They are summarized as follows: 1) prolonged postictal state, 
patients in this group usually become conscious within 6 hours with complete neurological 
recovery. 2) covert status epilepticus, patients in this group are at high risk of aspiration 
resulting from hypoxic and hypercarbic status caused by hyperventilation. The length of the 
seizure will determine the patients’ neurocognitive outcome. 3) severe metabolic 
derangement, deaths of patients were reported to be highly related to hypoglycemia and 
acidosis. 4) primary neurological syndrome, coma which may be caused by intracranial 
sequestration may persist for one to two days, often accompanied by intracranial 
hypertension (Marsh, English et al. 1996; Idro, Marsh et al. 2010).  
Epilepsy. The incidence of epilepsy occurs in around 10% of children months to years after 
exposure to hypoxia (Ngoungou and Preux 2008; Birbeck, Molyneux et al. 2010), and 
increases with time (Opoka, Bangirana et al. 2009). Epilepsy in malaria is believed to be 
caused by the focal hypoxic/ischemic neural injury or global ischemic injury (Newton, 
Peshu et al. 1994; Crawley, Smith et al. 1996; Potchen, Birbeck et al. 2010). The morbidity of 
epilepsy is positively associated with the timing of exposure to hypoxia (Ngoungou and 
Preux 2008; Opoka, Bangirana et al. 2009). However, behavior and neuropsychiatric 
disorders did not differ significantly (Birbeck, Molyneux et al. 2010).  
Malaria prophylaxis using sulphadoxine-pyrimethamine combined with amodiaquine was 
reported to improve cognitive function and school performance in clinical trials when 
compared to placebo groups (Clarke, Jukes et al. 2008). Similar phenomenon was found in 
an animal study by Reis et al (Reis, Comim et al. 2010), who support the view that cognitive 
dysfunction is sustained after rescue treatment in PbA-infected CM-sensitive C57BL/6 mice, 
an animal model for CM. In addition, treatment of CM-sensitive C57BL/6 mice with 
additive antioxidants such as malondialdehyde, MDA and conjugated dienes along with 
chloroquine prevented the development of persistent cognitive damage. This indicates that 
cognition problems may be associated with deleterious reactive oxygen species released 
during infection. 
4. Effects of cellular and humoral components in CM pathogenesis 
4.1 Endothelial cells and parasitized red blood cells 
Endothelial cells. One major feature of CM is the sequestration of pRBCs in brain 
microcirculation through adhesion between pRBCs and endothelial cells. The adhesion of 
falciparum parasitized erythrocytes to the human cerebral microvascular endothelium 
enables the parasites to avoid splenic clearance (D'Ombrain, Voss et al. 2007) providing the 
biological basis for the sequestration of pRBCs, and the major feature of CM. The surface 
receptors on endothelial cells are responsible for adhesion. The major surface receptors on 
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endothelial cells are Intercellular Adhesion Molecule 1 (ICAM-1) and CD36 (Collins, Read et 
al. 1995; Tripathi, Sullivan et al. 2006; Tripathi, Sha et al. 2009). CD36 is an 88-kDa integral 
protein found on the surface of not only endothelial cells, but adipocytes, platelets, 
monocytes, and macrophages. ICAM-1 is a 90–115 kDa transmembrane glycoprotein 
expressed on a variety of cell types including endothelial cells (Ochola, Siddondo et al. 
2011). Other endothelial surface antigens include PECAM-1, hyaluronic acid, chondroitin 
sulfate A (CSA), thrombospondin (TSP),ǂǎǃ3 and E-selectin, P-selectin, vascular cell 
adhesion molecule-1 (VCAM-1) (Schofield and Hackett 1993; Ho, Hickey et al. 2000; Craig 
and Scherf 2001; Yipp, Hickey et al. 2007). The sequestration of pRBCs in brain 
microcirculation in CM is due to the erythrocyte membrane protein 1 (pfEMP-1) expressed 
on P.falciparum parasitized RBCs adhere to endothelium through the endothelial surface 
receptors (Kang and McGavern 2010), mainly ICAM-1 and CD36. The interactions between 
pRBCs (not normal erythrocytes) and vascular endothelium through cellular adhesion 
molecules induce the deleterious endothelial cell responses (Combes, El-Assaad et al. 2010), 
including inflammation, endothelial activation, and apoptosis of microvascular endothelial 
cells resulting in the disruption of the blood-brain barrier (Idro, Marsh et al. 2010) in P. 
falciparum malaria. Apoptosis sequentially occurred in different cells. In murine models, 
apoptosis occurs in endothelial cells first, and is followed by neuronal and glia cells 
(Lackner, Burger et al. 2007). P. falciparum-pRBCs increase the expression of ICAM-1 and 
CD36 (Collins, Read et al. 1995; Tripathi, Sullivan et al. 2006; Tripathi, Sha et al. 2009) which 
strengthens sequestration, probably through NF-kappa B (Collins, Read et al. 1995; Tripathi, 
Sullivan et al. 2006; Tripathi, Sha et al. 2009) and MAP Kinase activation (Yipp, Robbins et 
al. 2003). In addition, pRBC adhesion to endothelium was found to up regulate several TNF-
superfamily genes and apoptosis-related genes such as Bad, Bax, caspase-3, SARP2, 
DFF45/ICAD, IFN-g receptor2, Bcl-w, Bik, and iNOS (Pino, Vouldoukis et al. 2003). It is 
worthy to note that direct contact between pRBC and microvascular EC may not be required 
for triggering apoptosis, because soluble factors released from parasitized erythrocytes have 
apoptotic effects on HBVEC and neuroglia cells (Wilson, Huang et al. 2008). The 
heterogeneity of endothelium in various locations of the body, characterized by the 
difference in expression levels of CD36 or ICAM-1 would probably determine the type and 
severity of malaria. Most recent results indicated that increased binding to CD36 by 
parasites is associated with uncomplicated malaria, since little CD36 is expressed on brain 
microvasculature (Ochola, Siddondo et al. 2011); while binding to ICAM-1 by parasites is 
increased and is associated with cerebral malaria (Ochola, Siddondo et al. 2011). Chilongola 
et al argued Ochola’s finding, and they suggested that CD36 deficiency may protect against 
falciparum malarial anemia (Chilongola, Balthazary et al. 2009). Further studies are required 
to clear out these arguments. Another big change in endothelial cells in CM is the damage of 
microvasuclar repair which is associated with low levels of circulating endothelial 
progenitor cells (CD34+/VEGF2+ and CD34+/CD133+) (Gyan, Goka et al. 2009). Together, 
activation of endothelial cells in brain vascular system by pRBC is one of the key events 
leading to encephalopathy. 
Parasitized red blood cells. pfEMP-1, a variable antigen expressed by P. falciparum (D'Ombrain, 
Voss et al. 2007), is encoded by the var-gene family of P. falciparum (Ikenoue, Kawazu et al. 
2002). As we described before, this knob protein plays a significant role in the 
pathophysiology of CM (Sharma 1997). pfEMP-1protein (Ikenoue, Kawazu et al. 2002) 
interacts with the endothelial cell through adhesion molecules in a receptor-ligand 
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dependent manner (D'Ombrain, Voss et al. 2007). Ultrastructural studies found an 
attachment between pRBC knobs and endothelial cell microvillus protrusions (Tripathi, 
Sullivan et al. 2006). pfEMP-1 has been considered a good candidate antigen for vaccination 
and a molecular therapeutic target to reverse the cytoadherence process (Sharma 1997). In 
addition, PfEMP-1 suppresses the production of the cytokine interferon-gamma (IFNǄ) 
produced by human peripheral blood mononuclear cells (ǄǅT, NK, and ǂǃT cells), which is 
a receptor (CD36)- independent (D'Ombrain, Voss et al. 2007). Down-regulation of the 
proinflammatory IFN-Ǆ responses has some beneficial effects for parasite growth. Taken 
together, changes in RBCs phenotype by falciparum infections trigger activation of cerebral 
microvascular endothelial cells resulting in falciparum related encephalopathy. 
4.2 Leukocytes 
Monocyte sequestration has recently been acknowledged to play a role in human CM and 
murine ECM (Grau, Fajardo et al. 1987; Combes, El-Assaad et al. 2010). Fatal malaria caused 
by P. falciparum is associated with both neutrophil activation and subsequent endothelial 
damage. For example, apoptosis induced by secretory products of neutrophils plays a key 
role in endothelial cell damage (Hemmer, Lehr et al. 2005). An antioxidant such as ascorbic 
acid and a protease inhibitor such as ulinastatin have been used to dramatically decrease 
falciparum-activated neutrophil-associated endothelial apoptosis (Hemmer, Lehr et al. 2005). 
The role of CD4+, CD8+, NKT and σǄT cells will be described elsewhere (see 4.5 Immunity 
to malaria).  
4.3 Platelets  
Endothelial cell activation plays an important role in the pathogenesis of cerebral malaria. 
Rosetting pRBCs bind to the endothelial cells and occlude microvessels in the brain (Cox 
and McConkey 2010). Therefore, it is not surprising that thrombocytopenia is a common 
feature in both murine ECM and human CM (Wassmer, Combes et al. 2003; Combes, El-
Assaad et al. 2010). Thus, it is essential to understand the association between platelets, 
pRBCs, leukocytes and endothelial cells in CM. CM is characterized by the accumulation of 
circulating cells including platelets within brain microvessels (Faille, Combes et al. 2009). 
Sequestration and accumulation of platelets in various organs, especially in the brain may 
partly explain the decrease in platelet count in circulation (Wassmer, Combes et al. 2003; 
Combes, El-Assaad et al. 2010) in malaria disease.  
There is increasing evidence that platelets contribute to the pathogenesis of cerebral malaria. 
Platelets modulate cytoadherence of pRBCs to brain endothelial cells in vitro (Faille, Combes 
et al. 2009). Animal studies indicate that blocking platelet function in mice is protective 
against severe malaria (Sun, Chang et al. 2003; van der Heyde, Gramaglia et al. 2005; 
Wassmer, Combes et al. 2006). Platelets and endothelial cells share common receptors, such 
as CD36, the complement receptor gC1qR/HABP/p32, and PECAM-1. CD36 and PECAM-1 
are receptors for pRBCs (Treutiger, Heddini et al. 1997; Pain, Ferguson et al. 2001; Biswas, 
Hafiz et al. 2007). Interactions between PfEMP1 on Plasmodium and CD36 on platelets 
possibly lead to platelet activation. The platelet activation aggregates pRBCs and platelets 
resulting in occlusion of microcirculation and activation of the endothelial cells (Cox and 
McConkey 2010). gC1qR/HABP/p32 interacts with both pRBCs and platelets potentiating 
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clumping of pRBCs (Biswas, Hafiz et al. 2007). The pathogenic role of platelets can be 
summarized as follows. First, in vitro cocultures from Wassmer et al (Wassmer, de Souza et 
al. 2006) showed that platelets or pRBC have a direct cytotoxic effect on TNF- or LT-alpha-
activated human brain vascular endothelial cells (HBVEC); second, platelets potentiate the 
cytotoxicity of pRBC activated HBVEC cells. Both permeability and trans-endothelial 
electrical resistance (TEER) are strongly affected, and the apoptosis rate of HBVEC cells 
dramatically increase. Inhibition of platelet adherence to brain microvessels protects against 
severe P. berghei malaria (Sun, Chang et al. 2003; van der Heyde, Gramaglia et al. 2005); 
third, studies evaluating interactions of platelet-RBC-endothelium suggest that pathogenic 
effects of platelets are not caused by adherence to the endothelial cells but result from the 
regulation of cytokine production (van der Heyde, Gramaglia et al. 2005; Cox and 
McConkey 2010). It has also been reported that there are more than 300 biologically active 
proteins in platelet extracts (Coppinger, Cagney et al. 2004), which play a crucial role in 
activation of endothelial cells (Coppinger, Cagney et al. 2004). As such, platelets can increase 
leukocyte adhesion to endothelial cells via IL-1, fibrinogen, ICAM-2 and P-secletin (McEver 
2001); fourth, micro-particles released from platelets can increase adhesion between 
endothelium and leukocytes and platelets via ICAM-1 (Barry and FitzGerald 1999; Combes, 
El-Assaad et al. 2010). 
However, effects to target platelets as therapy for cerebral malaria have resulted in 
controversy. Some studies argue that platelets have a protective role in malaria (Polack, 
Delolme et al. 1997; Wassmer, Taylor et al. 2008), while others argue the opposite view. Such 
inconsistencies might be explained by the different roles platelets play. For example, platelet 
activation will produce thrombocytopenia, which may be an adaptive response to platelet-
induced RBC clumping (Wassmer, Taylor et al. 2008). 
4.4 Immunity to malaria 
Immune responses are crucial factors in the pathophysiology of cerebral malaria, both in its 
initiation and progression. Parasite-triggered immune response and inflammation are 
considered to be a probable cause of death from CM associated encephalopathy. Innate 
immunity is generated by neutrophils, NK, NKT, dentritic cell (DCs) and σǄT cells; while 
adaptive immunity is produced by CD4+, CD8+ T cells. B cells and NK cells are not 
requisite for CM pathology (Yanez, Manning et al. 1996), but NK cells are involved in 
CXCL10-induced CXCR3+T cells trafficking leading to cerebral diseases and fatalities 
(Hansen, Bernard et al. 2007). NKT cells are specialized cells coexpressing NK and T cell 
receptors. They produce high levels of IFN-Ǆ and IL-4 after activation, and therefore 
influence Th1/Th2 immune responses. Thus, the polarization of Th1/Th2 immune 
responses will determine malarial fatalities (Hansen, Siomos et al. 2003). In a mouse model 
utilized by Seixas et al, DCs are activated in response to pRBCs internalization, and are 
important in shaping the adaptive immune response to severe malaria (Seixas, Moura 
Nunes et al. 2009). 
ECM involving P. berghei ANKA is considered a T cell-mediated disease. Both CD4+ and 
CD8+ T cells are involved in ECM (Belnoue, Potter et al. 2008). Treatment with anti-CD4 or 
anti-CD8 antibodies protected against ECM (Hermsen, van de Wiel et al. 1997). Studies in 
malaria patients also indicate higher frequencies of peripheral blood CD4(+) Foxp3(+) 
CD25(+) regulatory T (Treg) cells which correlate with increased blood parasitemia (Haque, 
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Best et al. 2010). In contrast, CD4+ natural regulatory T cells [CD4(+) Foxp3(+) CD25(+), 
Treg] in animals prevent cerebral malaria via CTLA-4 (but not IL-10) when expanded in 
vivo. In addition to CD4+ T cells, studies from a murine CM model also confirmed that 
CXCL10/CXCR3 interactions in the pathogenesis of fatal CM is through the recruitment and 
activation of pathogenic CD8+ T cells (Belnoue, Potter et al. 2008; Van den Steen, Deroost et 
al. 2008). The reason why CXCR3-/- mice were resistant to CM is potentially due to a 
reduction in the number of CD8+ T cells (Miu, Mitchell et al. 2008). Consistent with this, 
adoptive transfer of CD8+ cells abrogated protection of CM in CXCR3-/- and CXCL10-/- 
mice against P. berghei-mediated ECM. CD8+ cytotoxic T cells are involved in the disruption 
of BBB by perforin-dependent process. Interestingly, only CD8+ cells which were located in 
microvessels, expressed perforin, induced granule exocytosis and cytolysis (Nitcheu, 
Bonduelle et al. 2003; Miu, Mitchell et al. 2008), and activated cytotoxicity in a Fas 
dependent pathway (Nitcheu, Bonduelle et al. 2003; Miu, Mitchell et al. 2008). ECM 
induction was not only dependent on CD8(+) T cell-derived perforin but also on granzyme 
B (GzmB) (Haque, Best et al. 2011). CD8+ T cell-mediated CM pathology is characterized as 
organ-specific; it only occurs in the brain not the liver (Haque, Best et al. 2011). McQuillan et 
al (McQuillan, Mitchell et al. 2011) indicated that protection against CM was associated with 
a reduction in the accumulation and activation of CD8+ T cells in the cerebral 
microcirculation, along with reduction in malaria parasite burden in the same area 
(McQuillan, Mitchell et al. 2011). A breakthrough in malaria immunity research is that 
classical anti-plasmodial drugs act on the immune system in addition to their anti-
plasmodial activities. Quinine treatment reduced local cytokines and chemokines and 
coincided with protection against the disease (McQuillan, Mitchell et al. 2011). Artemisinin 
and its derivatives have been shown to reduce CD4+ and CD8+ T cell inflammatory 
responses (Veerasubramanian, Gosi et al. 2006; Wang, Tang et al. 2007; Wang, Qiu et al. 
2007; Xu, He et al. 2007). Yanez et al indicated that Ǆǅ T cells, in addition to CD4+ and CD8+ 
T cells, have an essential role to play in the pathogenesis of CM (Yanez, Batchelder et al. 
1999).  
4.5 Astrocytes, microglia, blood brain barrier 
Studies from a rodent model and human postmortem tissue suggest that the activation of 
astrocytes and microglial cells occurs during pathogenesis of CM (Medana, Hunt et al. 1997; 
Medana, Day et al. 2002; Medana and Turner 2006; Szklarczyk, Stins et al. 2007). 
Accumulation of macrophages and proliferation of microglial cells in the brain play 
important roles in CM. They increase the adherence of pRBCs to the cerebral 
microvasculature by secretion of proinflammatory mediators, disruption of BBB, and 
recruitment of inflammatory cells to the local area, resulting in the brain pathophysiological 
changes in these patients. An elegant study on the retina by Medana et al (Medana, Chan-
Ling et al. 1996; Medana, Chan-Ling et al. 2000) emphasized the importance of the immune 
system in the activation of glial cells and consequently in the formation of CM. Because the 
retina and the brain share similarities in development and function, they used retinal 
astrocytes and microglial cells to study the function of astrocytes and microglia in the 
pathogenesis of ECM (Medana, Chan-Ling et al. 1996; Medana, Chan-Ling et al. 2000). 
Activation of astrocytes and microglia were both observed during fatal murine cerebral 
malaria using the retinal whole-mount technique (Medana, Chan-Ling et al. 1996; Medana, 
Chan-Ling et al. 2000). They found that the disruption of blood retinal barrier (BRB)/BBB by 
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parasites initiated morphological and distributional changes in astrocytes and microglia. 
However these mild changes and redistribution were not sufficient for the development of 
cerebral pathology. The loss of astrocyte ensheathment of vessel segments and the reactive 
microglia changes resulting in severe cerebral pathology will require immune system 
activation triggered by the malaria parasites (Medana, Chan-Ling et al. 1996; Medana, Chan-
Ling et al. 2000). 
Activated astrocytes and microglial cells are capable of secreting a wide range of 
cytokines/chemokines, expressing MHC class II and co-stimulatory molecules (Dong and 
Benveniste 2001; Combes, El-Assaad et al. 2010). Thus they contribute to inflammatory 
responses within the brain parenchyma in CM (Deininger, Kremsner et al. 2002). Microglia 
and astrocytes produce TNF-alpha during the course of the disease (Medana, Hunt et al. 
1997), which plays a key role in the pathogenesis of fatal CM (Lucas, Lou et al. 1997). 
Astrocytes express TNF receptor 1 (TNFR1), TNF receptor 2 (TNFR2), IL-1 receptor 1, IFN 
ǂ/ǃ receptor, IFN-Ǆ receptor, and macrophage colony-stimulating factor (M-CSF) receptor 
(Tada, Diserens et al. 1994). TNF-ǂ induces astrocytes to generate and secret colony 
stimulating factors M-CSF, granulocyte colony-stimulating factor (G-CSF) and granulocyte 
macrophage colony-stimulating factor (GM-CSF), IL-6 and TNF-ǂ itself (Benveniste 1992). 
TNF-ǂ and IL-1 induce astrocytes to produce pro-inflammatory cytokines and nitric oxide 
(Aloisi, Borsellino et al. 1995). Nevertheless, in vivo, astrocytes limit the immune response 
within the central nervous systems (CNS) and initiate repair processes (Eddleston and 
Mucke 1993; Mucke and Eddleston 1993). Microglia, when stimulated by LPS and IFN-Ǆ 
(Giulian, Baker et al. 1986; Frei, Siepl et al. 1987), produce and release IL-1 (Giulian and 
Lachman 1985; Giulian, Baker et al. 1986; Giulian, Young et al. 1988), IL-6 and TNF-ǂ (Frei, 
Malipiero et al. 1989; Medana, Hunt et al. 1997). IL-1 is mitogenic to astroglia (Giulian, Baker 
et al. 1986). In malaria, any factors (such as CD8+T cells) inducing damage to the 
microvascular endothelium can result in the leakage of cytokines, malaria antigens and 
other potentially harmful molecules across the BBB into the brain parenchyma. All of these, 
in turn, result in the activation of microglia and the activation and apoptosis of astrocytes 
(Hunt, Golenser et al. 2006) to exacerbate the CM syndrome.  
The degree of immune activation and degeneration of glial cells reflect the extent of 
neurological complications in murine ECM (Medana, Chaudhri et al. 2001). Astrocyte 
disruption will cause acute or chronic damage to brain function. Damage to astrocytes, a 
major source of kynurenic acid may result in reduced production of the neuroprotectant 
molecule kynurenic acid (Medana, Hien et al. 2002; Medana, Day et al. 2003; Hunt, Golenser 
et al. 2006), causing a decrease in its ratio relative to the neuroexcitotoxic molecule 
quinolinic acid, which might contribute to some of the neurological symptoms of ECM and 
CM (Medana, Hien et al. 2002; Medana, Day et al. 2003; Hunt, Golenser et al. 2006). 
Redistribution, changes in gene expression, and the death of astrocytes have all been 
reported in human CM and ECM (Medana, Idro et al. 2007). Astrocyte ensheathment of 
vessels was associated with a big increase in BBB permeability that occurs at the time of 
neurological complications in the murine models of malaria. The loss of astrocyte processes 
was associated with the adherence of monocytes to the vascular endothelium, suggesting 
that toxic products produced by monocytes might play a role in astrocyte degeneration 
(Medana, Chaudhri et al. 2001). Microglia were found to be concentrated around capillaries 
in the grey matter. However microglia containing neutral lipid and iron pigment were 
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found in large perivascular lesions in the white matter. In addition, microglia were 
associated with perivenular haemorrhages (Medana, Chaudhri et al. 2001). Activation of 
microglia might damage astrocytes via Fas/FasL interactions (Potter, Chan-Ling et al. 2006). 
These findings underline the important contribution within the CNS of glia and their 
secreted products, such as cytokines, in the development of human CM. 
4.6 Microparticles (MP) and CM 
Eukaryotic cells, after activation by a variety of stimuli, shed components of their plasma 
membranes into circulation. Such submicron particles may include cytoplasmic and nuclear 
(Roos, Gennero et al. 2010) elements and are known colloquially as microparticles (MPs) 
(Barry and FitzGerald 1999; Doeuvre, Plawinski et al. 2009). Monocytes, lymphocytes, 
endothelial cells, erythrocytes, granulocytes and platelets have been shown to vesiculate 
either in vitro or in vivo (Barry and FitzGerald 1999). MPs, exposing the phospholipid 
phosphatidyl serine (PS) on the external surface of the cell membrane (Schroit, Madsen et al. 
1985), have been identified increasingly in a broad range of diseases (Roos, Gennero et al. 
2010) where vascular dysfunction and inflammation are important pathophysiological 
mechanisms (Lynch and Ludlam 2007).  
Human studies (Combes, Taylor et al. 2004) on MPs in CM were first conducted in 
Malawian patients demonstrated that increased release of circulating endothelial cell-
derived MP- (EMPs) correlate with malaria severity. EMPs are increased in patients with 
severe CM complicated with coma (Barry and FitzGerald 1999; Doeuvre, Plawinski et al. 
2009), but not with those with malaria complicated by anemia. The high concentrations of 
plasma TNF in patients with CM may enhance endothelial vesiculation both in vivo and in 
vitro (Combes, Simon et al. 1999). In a P. berghei (PbA) infected ECM mouse model, ABCA1, 
a gene determining the lipid transbilayer remodeling was found to be responsible for 
external exposure of PS to generate EMPs in malaria (Combes, Coltel et al. 2005).  
Apart from endothelium, other cell types including erythrocytes, platelets and monocytes 
also release microparticles and contribute to the pathogenesis in patients with malaria. Red 
blood cell–derived microparticles (RMPs) were increased in patients with P. falciparum, P. 
vivax, and P. malariae compared with healthy controls (Nantakomol, Dondorp et al. 2011). 
RMPs were highest in severe falciparum malaria patients. RMPs released from either 
parasitized erythrocytes or uninfected red blood cells (URBCs) are pathogenic. pRBCs 
released 10 times more RMPs than did URBCs. Overall, the majority of RMPs were derived 
from URBCs (Nantakomol, Dondorp et al. 2011). In vitro, RMPs production increased as the 
parasites matured. Some biological molecules can trigger RMPs release. For example, 
hemin-mediated oxidative stress was associated with the production of RMPs (Nantakomol, 
Dondorp et al. 2011). Hemin induced RMP formation in URBCs was inhibited by N-
acetylcysteine. In PbA infected C57 BL/6 mice (Couper, Barnes et al. 2010), malaria parasite-
derived plasma MPs which are derived primarily from pRBCs, induced severe 
inflammation through potent macrophage activation as indicated by CD40 up-regulation 
and TNF production. Consistent with this, in vitro experiments confirmed that these MPs 
produced higher levels of macrophage activation than intact infected red blood cells. MPs 
driven macrophage activation was dependent on MyD88 and TLR-4 signaling (Couper, 
Barnes et al. 2010). 
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Platelets vesiculate particles following activation by complement proteins C5b-9 (Sims, 
Faioni et al. 1988). It was demonstrated that platelet-derived MPs (PMPs) may modulate 
adhesive interactions between endothelial cells and monocytes resulting in human 
atherosclerosis and inflammation (Sims, Faioni et al. 1988). In 2009, Grau’s group (Faille, 
Combes et al. 2009) showed that PMPs derived from activated platelets are able to bind to 
falciparum-infected RBCs (pRBCs), thereby transferring platelet antigens to the PRBCs 
surface. PMPs uptake by HBVECs induce changes in the endothelial phenotype, 
dramatically increasing pRBCs cytoadherence to HBVECs and playing a role in the 
pathogenesis of P.falciparum (Faille, Combes et al. 2009). PMPs adherence is specific to 
pRBCs, and require the expression of the pfEMP variant on pRBCs. Not surprisingly, this 
binding to pRBCs decreases either after digestion of pRBCs surface proteins by trypsin or 
neutralization of PMPs with a mAb to platelet-endothelial cell adhesion molecule-1 (CD31) 
and glycoprotein IV (CD36) (Faille, Combes et al. 2009). 
In a recent human study conducted in Douala, Cameroon (Pankoui Mfonkeu, Gouado et al. 
2010) indicated that not only plateletic, erythrocytic and endothelial but also leukocytic MPs 
levels were elevated in CM patients with neurological dysfunctions but return to normal 
levels after recovery of patients. This vesiculation in the vascular compartment is a 
characteristic of CM but not of SMA. Platelet MPs were the most abundant and their levels 
significantly correlated with the depth of unconsiousness and thrombocytopenia. Their 
findings raise the importance of MP as a biomarker of cerebral involvement and the 
importance of the intervention to block MPs production as a new therapeutic strategy in CM 
(Pankoui Mfonkeu, Gouado et al. 2010). Whether MPs can be detected and identified in CSF 
or other body compartments (saliva) as a predictor of cerebral tissue damage is unclear. 
Various techniques including flow cytometry (FC), enzyme-linked immunosorbent assay 
(ELISA), and functional assays have been used to detect circulating MPs (Azevedo, Pedro et al. 
2007; Lynch and Ludlam 2007). 1) FC is the most common method to quantify MPs. The 
advantages of FC are simplicity and the wealth of data generated from study samples. 
However, the small size of MPs and the lack of uniformity in methodology complicate 
measurement of outcomes. As MPs contain surface and cytoplasmic contents of the parent 
cells (particles which reflect their cell of origin and its state of activation) and contain 
phosphatidylserine, antibodies against specific cell surface markers and annexin V can be used 
for detection. FC can be used to quantify and identify MPs of different cellular origin 
(Doeuvre, Plawinski et al. 2009; Campos, Franklin et al. 2010; Roos, Gennero et al. 2010). 2) 
Since FC is too expensive and not feasible in most clinical centers, an ELISA for PMPs has 
recently been developed as a viable alternative for the clinical measurement of PMPs levels 
(Shirafuji, Hamaguchi et al. 2008; Nomura, Shouzu et al. 2009). ELISA can be performed after 
freezing the sample, allowing samples to be batched for assays, and thus reducing expenses. 
The PMPs ELISA kit used two monoclonal antibodies against glycoprotein CD42b and CD42a 
(Shirafuji, Hamaguchi et al. 2008; Nomura, Shouzu et al. 2009). One unit/milliliter of PMPs 
was defined as 24,000 platelets/ml of solubilized platelets in this ELISA system. 
Recently, new methods have been introduced to assay for MPs. SYTO 13 is a more sensitive 
quantitative assay for MPs (Ullal, Pisetsky et al. 2010). The emergence of SYTO13 dyes for 
detection of MPs is attributed to limitation of FC with either light scatter or surface marker 
staining due to the small size of MPs (0.05 to 1.5µm). The SYTO 13 assay is based on the 
principle that MPs contain DNA and RNA, thus allowing SYTO13 to bind both DNA and 
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RNA within particles. STYO 13 enhanced the ability of the detection for particles 1.5–2.9 
times more than did light scatter in FC (Ullal, Pisetsky et al. 2010). Circulating nucleic acids 
(CNAs) have been increasingly recognized as powerful diagnostic and prognostic tools for 
various inflammatory diseases (Ullal, Pisetsky et al. 2010). For example, CNAs level as 
measured by amplification of the human telomerase reverse transcriptase (hTERT) gene, or 
the dsDNA quantification were significantly increased in plasma from P. vivax patients 
compared with healthy controls (Ullal, Pisetsky et al. 2010). No such report is available for 
malaria encephalopathy. 
5. Molecular pathogenesis of CM 
5.1 Crosstalk and signaling pathways in CM  
5.1.1 Cytokines and chemokines 
Cytokines and chemokines exert both protective and harmful effects during CM 
pathogenesis. Antigen-like components released from malaria induce both pro and anti-
inflammatory cytokines and chemokines. The balance between these biological mediators is 
crucial for parasite control and for the contribution to the pathogenesis of severe malaria 
and CM encephalopathy (Idro, Marsh et al. 2010).  
5.1.1.1 Th1 and Th2 cytokines 
The harmful, dysregulated immune response resulting in CM or ECM is mainly due to the 
imbalance between Th1 and Th2 types with overproduction of some cytokines, such as IFNǄ 
combined with underproduction of others such as IL-10. 
Th1 cytokines include IFN-Ǆ and lymphotoxin (TNF-beta). CD4+ Th cells are subdivided 
into two different types, known as type 1 Th (Th1) and type 2 Th (Th2). Th1 cells produce 
cytokines, such as IL-2, IFN-Ǆ (at a later stage also by CD8+ cytotoxic T cells), tumor necrosis 
factor (TNF-alpha) and TNF-beta, which cause the activation of macrophages and the 
process of opsonization and cytotoxicity (Romagnani 1997). In contrast, Th2 cells are 
considered to play a regulatory and protective role, since cytokines produced by these cells 
[e.g., IL-10, transforming growth factor-ǃ (TGF-ǃ), IL-4 and IL-13] inhibit the production of 
Th1 cytokines and activation of macrophages (Romagnani 1997; Hunt and Grau 2003). A 
recent study in Ghanaian and Indian patients demonstrated an association between fatal 
CM and increased serum and cerebrospinal fluid (CSF) levels of proinflammatory and 
proapoptotic factors including CXCL10, IL-1ra, sTNFR1, sTNFR2, sFas and decreased serum 
and CSF levels of neuroprotective angiogenic growth factors (PDGFb) (Armah, Wilson et al. 
2007). In children with CM, cytokine TNF-ǂ level in CSF is associated with subsequent 
neurological and cognitive morbidity (John, Panoskaltsis-Mortari et al. 2008). 
Th2 cytokines include IL-4, IL-10 and TGF-beta. IL-10 not only plays an important role in 
cerebral malaria pathogenesis (Yanez, Manning et al. 1996; John, Panoskaltsis-Mortari et al. 
2008), but also is associated with asymptomatic malaria in pregnant women (Wilson, 
Bythwood et al. 2010). TGFǃ isoforms were shown to accumulate in the brain of CM 
patients. Members of the TGFǃ cytokine family have been associated with the control of 
malaria infection and parasite growth (Omer and Riley 1998; Hunt and Grau 2003; 
Chaiyaroj, Rutta et al. 2004); TGFǃ1 levels were significantly reduced in peripheral plasma 
of children with CM (Omer and Riley 1998; Hunt and Grau 2003; Chaiyaroj, Rutta et al. 
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2004). However, a mechanism for CM was found through TGFǃ1 released from activated 
platelets, by which TGFǃ1 induces TNF-mediated apoptosis in human brain endothelium 
(Wassmer, de Souza et al. 2006).  
Other host serological factors contain CXCL10, interleukine (IL-1), IL-6, IL-8, MCP-1, 
RANTES. In 2003, CXCL10 was first reported to be a host-protective factor in ECM (Hunt 
and Grau 2003). CXCL10 expression was expressed early in either cerebral malaria-
susceptible or -resistant strains of mice to P. berghei ANKA infection (Chen and Sendo 2001; 
Hanum, Hayano et al. 2003). More recently, a pioneering study conducted both in India and 
Ghana, identified CXCL10 as a serum and CSF biomarker associated with increased risk of 
fatal P. falciparum-mediated CM in humans (Armah, Wilson et al. 2007; Jain, Armah et al. 
2008; Wilson, Huang et al. 2008). Subsequently, studies from a murine CM model also 
confirmed the importance of CXCL10/CXCR3 interactions in the pathogenesis of fatal CM 
through the recruitment and activation of pathogenic CD8+ T cells (Belnoue, Potter et al. 
2008; Van den Steen, Deroost et al. 2008). CXCL10-/- and CXCR3-/- mice are partially 
resistant to P. berghei-mediated CM. Furthermore, the study also revealed that CXCR3-/- 
mice were resistant to CM as a result of a reduction in the number of CD8+ T cells (Miu, 
Mitchell et al. 2008). Adoptive transfer of CD8+ cells abrogated protection of CM in CXCR3-
/- mice while CXCL10-/- mice were partially resistant to P. berghei-mediated CM. A 
proposed cellular pathways of CXCL10-mediated severe malaria is presented in Figure 1 
[(Adapted with permission from Cytokine and Growth Review (Liu, Guo et al. 2011) ]. 
Endothelial cells, astrocytes and microglia are a prominent source of CXCL10 and CXCL9. 1) 
Through T cells sequestration (Belnoue, Kayibanda et al. 2002; Nitcheu, Bonduelle et al. 
2003; Campanella, Tager et al. 2008; Miu, Mitchell et al. 2008). CXCL10 could attract 
activated T cells and mediate Th1-type response, characterized by the sequestration of 
monocytes and T cells (mainly CD8+) in cerebral microvessels. Granule exocytosis and 
Fas/Fas ligand activation pathways are two distinct mechanisms involved in the death of 
brain endothelial cells by CD8+ lymphocytes. 2) Through NK cell sequestration (Hansen, 
Siomos et al. 2003; Hansen, Bernard et al. 2007), NK cells mediate direct cytotoxic activity or 
reconstitution capacity of T cells to migrate in response to CXCL10 to the CNS. 3) Through 
up-regulation of ICAM-1 on brain microvascular endothelial cells (Bauer, Van Der Heyde et 
al. 2002). LTǂ and IFN-Ǆ are required for PbA-induced endothelial ICAM-1 up-regulation 
and PbA-induced increased cytoadherence of sequestered of pRBC to the endothelium of 
cerebral vessels. This results in hypoxia, hemorrhage and pathology, and represents another 
potential mechanism of CM pathogenesis.  
CXCL10 is elevated in association with chills, rigors, anemia (Jain, Singh et al. 2009) and pre-
chloroquine/primaquine chemotherapy and disappears after chemotherapy against malaria. 
Interestingly, HIV infection increases susceptibility to malaria when CXCL10 levels are 
elevated (Chaisavaneeyakorn, Moore et al. 2002) while filariasis produces resistance to 
malaria by down-regulating CXCL10 (Metenou, Dembele et al. 2009). Recent studies suggest 
that altered levels of CXCL4 and CXCL10 play a prominent role in the pathogenesis of fatal 
CM and may be used as functional or surrogate biomarkers for predicting CM severity 
(Wilson, Jain et al. 2011). This remarkable link between increased CXCL10 and the severity 
of parasitic diseases suggest further studies needed to be conducted on the mechanisms 
involved. (Campanella, Tager et al. 2008). Our recent in vitro cell culture studies (Liu & 
Stiles, manuscript in review) revealed that Heme regulates CXCL10 at the transcriptional 
level [See 5.1.3.1 Heme/ Heme oxygenase-1 (HO-1)].  
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Fig. 1. Proposed cellular pathways in CXCL10-mediated severe malaria. 
IL-1 and IL-6 are key pathogenic factors in malaria (John, Panoskaltsis-Mortari et al. 2008). 
Significantly elevated levels of IL-1, G-CSF and monocyte chemoattractant protein-1 (MCP-
1) but not IL-8 have been reported in children who died of CM than children without the 
disease (UM) (John, Park et al. 2008). However, a study on the global transcriptome of 
HBVEC after exposure to P.falciparum-infected RBCs showed that proinflammatory 
molecule IL-8 together with CCL20, CXCL11, CXCL2 and IL-6 were increased more than 
100-fold consistent with the critical role of the endothelium in promoting leukocyte 
infiltration (Tripathi, Sha et al. 2009). Low levels of the chemokine RANTES are 
independently associated with mortality (John, Opika-Opoka et al. 2006). In summary, the 
role of cytokines/chemokines and corresponding receptor interactions appear to be highly 
associated with severity of CM encephalopathy. 
5.1.1.2 Angiopoiesis and CM (angiogenic/angiostatic factors) 
Vascular endothelial growth factor (VEGF) and Angiopoietin-1 (Ang-1)/ Ang-2. Severe and 
cerebral malaria are associated with endothelial activation (Conroy, Lafferty et al. 2009). The 
role of VEGF in CM encephalopathy remains to be clarified. Increased production of VEGF 
is able to trigger vascular leakage in the circulation of mice, and promote injury in ECM 
(Epiphanio, Campos et al.) although it can induce antiapoptotic proteins like Bcl2 in 
endothelial cells (Ferrara 2004). In our study performed in Indian angiogenic and anti-
apoptotic factors, VEGF was found to be negatively correlated with mortality associated 
with CM (Jain, Armah et al. 2008), and to be protective against fatal CM (Jain, Armah et al. 
2008). ANG-1 and ANG-2 are major regulators of endothelial activation and integrity 
(Conroy, Lafferty et al. 2009). CM patients have significantly lower ANG-1 levels, 
significantly higher ANG-2 levels and ANG-2/ANG-1 ratio than non-malaria or malaria 
patients without cerebral involvement (Conroy, Lafferty et al. 2009). ANG-2 has dual 
www.intechopen.com
 
Current Advances in Cerebral Malaria Associated Encephalopathy 
 
143 
functions depending on the activity of endogenous VEGF-A. Lobov et al (Lobov, Brooks et 
al. 2002) stated that VEGF acts through the conversion of ANG-2 stimulation from anti- to 
pro-angiogenic to regulate vascularity (Lobov, Brooks et al. 2002). ANG-2 in vivo increases 
capillary diameter, remodels the basal lamina, promotes proliferation and migration of 
endothelial cells, and stimulates sprouting of blood vessels when VEGF-A is activated; 
whereas, ANG-2 promotes endothelial apoptosis and vessel regression if the VEGF activity 
is inhibited. Plasma levels of ANG-1 and -2 predict cerebral malaria outcome in Central 
India (Jain, Lucchi et al, 2011). Malar J. 2011 Dec 23;10(1):383. 
5.1.1.3 Erythropoietin and CM 
Erythropoietin (Epo) regulates the production of new erythrocytes in blood trough binding 
to its receptor (EpoR) which is expressed on the cell surface of bone marrow erythroid 
precursors (Casals-Pascual, Idro et al. 2009). During this process, tissue hypoxia activates 
Epo gene expression (Casals-Pascual, Idro et al. 2009). Epo has recently been recognized as a 
tissue-protective cytokine (Brines, Grasso et al. 2004). The tissue-protective effects of Epo are 
mediated by EpoR located on neurons, astrocytes, microglia and endothelial cells (Masuda, 
Nagao et al. 1993; Masuda, Okano et al. 1994; Bernaudin, Nedelec et al. 2002; Sargin, El-
Kordi et al. 2011). In other words, the non-hematopoietic function of Epo occurs in organs 
outside the bone marrow such as brain, retina, spinal cord, peripheral nerves, heart, kidney, 
and skin (Ghezzi and Brines 2004; Maiese, Li et al. 2005; Arcasoy 2008; Casals-Pascual, Idro 
et al. 2009). In this case, hypoxia does not have a key role in the regulation of EpoR, whereby 
Epo, pro-inlammatory cytokines IL-1 and TNF regulate EpoR (Nagai, Nakagawa et al. 2001; 
Brines and Cerami 2005; Siren, Fasshauer et al. 2009). The distinct functions of Epo are 
thought to be mediated via different receptors (Brines, Patel et al. 2008; Casals-Pascual, Idro 
et al. 2009). EpoR homodimers induce the haematopoietic response, whereas tissue-
protective actions are induced by a heterocomplex composed of the Epo receptor and other 
cytokine receptors such as CD131, the beta-common receptor (mediating signals from GM-
CSF, IL-3 and IL-5) (Brines, Patel et al. 2008). The pleiotropic action of Epo through the 
heterodimeric EpoR causes anti-apoptotic, anti-inflammatory, anti-angiogenic and anti-
oxidatory effects in a variety of neuropathological disorders (Brines, Grasso et al. 2004; 
Hasselblatt, Ehrenreich et al. 2006), which might be potentially beneficial in CM. In the P. 
berghei-infected mouse model, Epo activated neural stem cells (NSC) and caused 
proliferation of NSC and neuronal precursor cells in sub ventricular zone (Core, Hempel et 
al. 2011). Emerging evidence has shown beneficial effects of recombinant human 
erythropoietin (rHuEpo) in both experimental and human CM (Casals-Pascual, Idro et al. 
2008; Casals-Pascual, Idro et al. 2009; Mishra and Wiese 2009). Experimental CM studies 
have shown that Epo increases survival, shortens coma recovery times (Bienvenu, Ferrandiz 
et al. 2008) and decreases the inflammatory response and neuronal apoptosis in the brain 
(Kaiser, Texier et al. 2006; Wiese, Hempel et al. 2008). Human studies in African children 
with CM have indicated that Epo prevents brain damage (Casals-Pascual, Idro et al. 2009) 
and protects against neurological sequelae (Casals-Pascual, Idro et al. 2008). Although a 
safety profile for short-term (7 days) administration of erythropoietin at high does 
(1,500U/kg/day during 3 days) combined to quinine have recently been assessed in Mali 
(Picot, Bienvenu et al. 2009), a multicenter study using Epo as an adjunctive therapy to 
improve survival during CM is necessary. In summary, the interactions between Epo and 
EpoR in organs outside bone marrow appear to contribute to the protection against fatal CM 
pathogenesis although the mechanism is not completely understood. 
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5.1.2 Signaling pathways in CM encephalopathy 
Cytoadherence between pRBC and endothelial cells is increased by up regulation of 
endothelial molecules such as ICAM-1, CD36 (Combes, El-Assaad et al.) in severe malaria. 
The proinflammaotry NF-kappaB pathway (Tripathi, Sha et al. 2009; Labbe, Miu et al. 2010), 
Src family kinase (Yipp, Robbins et al. 2003; Gillrie, Krishnegowda et al. 2007) and Rho 
kinase (Taoufiq, Gay et al. 2008) play certain roles in modulating the host response to P. 
falciparum, especially in the interaction between sequestered pRBC and specific endothelium 
[Fig. 2, Adapted with permission from Cytokine and Growth Review (Liu, Guo et al. 2011)]. 
A better understanding of host-parasite interactions will facilitate the development of novel 
strategies for interventions.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2. Kinases and transcription factors in cerebral malaria. 
5.1.2.1 Rho kinase signaling pathway 
Some endothelial cell surface receptors have an intracellular domain coupled to G-protein 
and Rho signaling (Taoufiq, Gay et al. 2008). GDP/GTP exchanges and the activation of 
RhoA activate its downstream molecule Rho kinase. Activated Rho A/Rho kinase pathway 
leads to endothelial dysfunction by increasing cell retraction (through phosphorylation of 
myosin light chain) and endothelial hyperpermeability (through tight junction). Rho kinase 
also downregulates PI3K/Akt/eNOS cell growth pathway (Taoufiq, Gay et al. 2008). Rho 
kinase inhibitor (HA-1077), a drug already in clinical use, was reported to decrease both NF-
kappaB activation and endothelial apoptosis (Taoufiq, Gay et al. 2008; Zang-Edou, Bisvigou 
et al. 2010), increase survival, and delay or prevent development of cerebral malaria 
(Waknine-Grinberg, McQuillan et al. 2010). 
5.1.2.2 NF-κB signaling pathway 
pRBCs exposure induced nuclear translocation of NF-κB in HBVEC, which is related to ICAM-
1 expression. In this way, pRBCs may increase their sequestration, thereby exacerbating CM 
(Tripathi, Sullivan et al. 2006). A global gene profile study on HBVECs after interaction with 
Endothelial 
Endothelial 
Endothelial 
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pRBCs emphasized that the proinflammatory NF-κB pathway was central to the regulation of 
the P.falciparum-modulated endothelium transcriptorme (Tripathi, Sha et al. 2009). 
5.1.2.3 Toll-like receptor (TLR) signaling pathway 
MyD88 is a necessary adaptor molecule for intracellular signaling induced by most TLRs 
(Coban, Ishii et al. 2007). TLR4, TLR9 and MyD88 were described to play a role in pro-
inflammatory responses to malaria infection following interaction of DC with the malaria 
parasite (Seixas, Moura Nunes et al. 2009). Both TLR4 and TLR9 besides MyD88 are required 
for complete DC activation, and consequently up regulation of co-stimulatory molecules, 
NF-κB nuclear tanslocation and production of cytokines (Seixas, Moura Nunes et al. 2009). 
Among the MyD88-dependent CM-related innate immunity signaling, TLR2 or TLR9 
increases susceptibility to CM-related mortality, suggesting that these two TLRs play a 
critical role in the pathogenesis, and not in protective immunity (Coban, Ishii et al. 2007). 
TLR2 stimulation with P. falciparum glycosylphosphatidylinositol (PfGPI) increases pRBCs 
uptake and clearance by macrophage as another example of the role of innate immunity 
responses to malaria (Erdman, Cosio et al. 2009).  
5.1.2.4 Peroxisome proliferator activating receptor (PPAR)/PKC signaling pathway 
PPAR-retinoid X receptor (PPARǄ/RXR) activated phagocytosis of pRBCs and decreased 
malaria-induced TNF-ǂ secretion by monocytes/macrophages (Serghides and Kain 2001). 
PPAR has been reported to inhibit the induction of inflammatory genes via PPARǄ-
dependent mechanisms, an effect mediated, at least partially, by inhibition of transcription 
factors NF-kB (Straus, Pascual et al. 2000). PfGPI from P. falciparum has also been shown to 
be a potent inducer of inducible NO synthase system through the activation of NF-kB 
(Schofield, Novakovic et al. 1996). 
5.1.2.5 Signal transducer and activator of transcription (STAT3) signaling pathway 
STAT3 is a signaling cascade activated by pro-inflammatory stimuli and cellular stresses. 
This protein located in the cytoplasm is in its inactive form and is activated via 
phosphorylation (pSTAT3) by the Janus tyrosine kinases (JAKs). The active form of STAT3 
quickly translocates to the nucleus. pSTAT3 is a potent negative modulator of the Th1-
mediated inflammatory response, and also an activator of a variety of genes which are 
important for immune modulation (Yu and Jove 2004; El Kasmi, Holst et al. 2006). Chen’s 
group has reported that lethal Plasmodium yoelii (P.yoelii) induced activation of STAT3 in the 
early phase of infection. The dominant pSTAT3 response may dampen the development of 
protective immunity, resulting in high parasitemia and death (Shi, Qin et al. 2008). Our data 
(Liu & Stiles, manuscript in review) showed that STAT3 is activated by PbA infection in vivo 
and Heme in vitro, while HO-1 regulates STAT3 signaling. 
5.1.2.6 TNF/TNFR (LTǂǃ/LTǃR) signaling pathway 
TNF, the most extensively investigated cytokine in CM, up regulates ICAM-1 expression on 
the cerebral vascular endothelial cells and enhances the cytoadhesion of pRBCs (Idro, Marsh 
et al. 2010). Local synthesis is enhanced close to the sequestration sites. TNF has dual 
functions in malaria: it may be cytoprotective in the early phase, but its sustained high levels 
leads to complications (Hunt and Grau 2003; Idro, Marsh et al. 2010). Signaling through TNF 
receptors activate the classic NF-κB/RelA pathway resulting in the expression of a large 
number of genes involved in inflammatory responses, cell adhesion or cell growth (Togbe, 
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de Sousa et al. 2008). Unfortunately, neither pentoxifylline, which reduces macrophage TNF 
synthesis, nor anti-TNF monoclonal antibody increased the survival of patients 
(Looareesuwan, Wilairatana et al. 1998; Wenisch, Looareesuwan et al. 1998; Idro, Marsh et 
al. 2010) although the coma period was shortened (Di Perri, Di Perri et al. 1995) or the levels 
of TNF/TNFR and IL-6 were decreased (Looareesuwan, Wilairatana et al. 1998; Wenisch, 
Looareesuwan et al. 1998). 
5.1.2.7 MAP kinase/ Src family kinase pathway 
MAPKs and downstream activation of the ERK and p38 pathways (not shown in Fig.2 for 
clarity) triggered by PfGPIs regulate TNF-ǂ and IL-12 production, two of the major 
inflammatory cytokines produced by macrophages stimulated with PfGPIs (Zhu, Wu et al. 
2009). Src-family kinase signaling was found to modulate the adhesion of P. falciparum on 
human microvasculature (Yipp, Robbins et al. 2003; Gillrie, Krishnegowda et al. 2007). A 
novel mechanism for the regulation of pRBCs adhesion on human microvascular 
endothelial cells is through CD36, Src-family kinase, and ectoalkaline phosphatase (Yipp, 
Robbins et al. 2003). 
5.1.2.8 Apoptosis-related genes 
See 4.1 Endothelial progenitor cells and endothelial cell markers  
5.1.3 Other signaling pathways  
5.1.3.1 Heme/Heme oxygenase-1 (HO-1) 
Recently, it has been shown that increased levels of free Heme produced during malaria 
infection induces inflammation that damages host vascular endothelium, which contributes to 
cerebral pathogenesis and acute lung injury (ALI) which are major features of fatal malaria 
(Epiphanio, Campos et al. ; Hunt and Stocker 2007; Pamplona, Ferreira et al. 2007; Pamplona, 
Hanscheid et al. 2009). Heme oxygenase (HO) is the rate-limiting step enzyme in the 
degradation of Heme groups to biliverdin, carbon monoxide (CO), and iron. HO-1 is also 
known as a heat shock protein 32 (hsp32), which is an integral membrane protein of the 
smooth endoplasmic reticulum (Lin, Weis et al. 2007), and is the only inducible isoform of HO. 
The up regulation of HO-1 provides protection against cellular stress including oxidative 
stress, heavy metal toxicity, UV radiation, and inflammation, thus preventing deleterious 
effects of Heme and mediating anti-inflammatory and antiapototic functions (Geuken, Buis et 
al. 2005; Datta, Banerjee et al. 2010). HO-1 may facilitate the repair of injured tissues through 
inhibition of infiltrating inflammatory cells (Datta, Dormond et al. 2007). Moreover, HO-1 that 
is induced by reactive oxygen species and nitric oxide (NO) has recently been shown to be 
involved in the regulation of angiogenesis (Pae, Oh et al. 2005; Bussolati and Mason 2006).  
The expression of HO-1 occurs at low levels in most tissues under physiological conditions 
(Ehrich and Eke 2007). HO-1 can localize to distinct subcellular compartments. Inducible HO 
activity appeared in the plasma membrane, cytosol, mitochondria (Ryter and Choi 2009), 
isolated caveolae and the nucleus (Kim, Wang et al. 2004) in cell culture models. Early studies 
indicate that HO-1 in the mitochondria and caveolae performs important biological and 
physiological functions (Ryter and Choi 2009), although the function of HO-1 in caveolae and 
the nucleus is not completely understood. The nuclear form of HO-1 serves potentially as a 
transcriptional regulator (Ryter and Choi 2009). Upon different stimuli of hypoxia, hemin or 
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Heme-hemopexin, HO-1 translocates to the nucleus. Nuclear translocation compromises HO 
activity, but nuclear localization of HO-1 protein functions to up regulate genes that promote 
cytoprotection against oxidative stress (Lin, Weis et al. 2007).  
Heme/HO-1 interactions have moved to center stage in CM research since 2007. At the time, 
Mota’s group reported that HO-1 and carbon monoxide (CO) suppressed the pathogenesis 
of ECM (Pamplona, Ferreira et al. 2007). HO-1 was then found to be capable of inhibiting 
vascular occlusion in transgenic sickle mice (another hemolytic disease) (Belcher, Mahaseth 
et al. 2006; Belcher, Vineyard et al. 2010). From these studies it seems that the ability of 
individuals to respond strongly in response to an increase in HO-1 may be a crucial 
endogenous protective factor. However, some studies refute the findings that HO-1 protects 
the development of ECM (Takeda, Kikuchi et al. 2005). Their data suggests that the 
frequency of short (GT)n alleles (<28 repeats), which may lead to high levels of HO-1, is 
markedly higher in CM patients (Takeda, Kikuchi et al. 2005). Moreover, liver stages of 
malaria infection was remarkably reduced in Hmox1-/- mice (Pamplona, Ferreira et al. 2007). 
These findings suggest that the regulated expression of HO-1 is quite complex in different 
tissues at different stages of the Plasmodium life cycle. Therefore further experimental and 
epidemiological studies are necessary to unveil the role of Heme/HO-1 in the severity of 
malaria. Our study (Liu & Stiles, manuscript in review) demonstrated that (1) infection of 
C57 BL/6 mice with PbA resulted in significant tissue damage. (2) Heme/HO-1 and 
CXCL10/CXCR3 are involved in the pathogenesis of severe malaria, such that the level of 
free Heme is linked to PbA infection in mice. (3) Expression of HO-1 in tissues may be 
protective against PbA induced Heme-associated damage. (4) High levels of CXCL10 are 
associated with ECM onset in PbA infected mice. (5) Heme up regulates HO-1 and CXCL10 
production in vitro, and regulates CXCL10 at the transcriptional level in vitro. (6) HO-1 
transcription was positively regulated by CXCL10. Overall, our results demonstrate that 
Heme and CXCL10 molecules as well as related signaling pathways play a very important 
role in inflammation and organ damage in malaria and CM encephalopathy.  
5.1.3.2 Arginine/Nitric oxide signaling pathway 
The role of Nitric oxide (NO) in malaria pathogenesis has been inconsistent. The 
relationship between NO activity and inducible NO synthase and pathogenesis is 
controversial (Anstey, Weinberg et al. 1996; Cramer, Nussler et al. 2005). NO exerts effects in 
host defense, neurotransmission, and vascular maintenance. NO is an effecter for TNF, and 
it is thought that inflammatory cytokines increase inducible NO synthase in brain 
endothelium resulting in increased NO production. NO is permeable to BBB, diffusing into 
brain tissue, and consequently impairing neurotransmission and may be an explanation for 
reversible comas (Clark, Rockett et al. 1992). These toxic molecules might contribute to the 
pathogenesis of severe and cerebral malaria (Clark, Hunt et al. 1986; Clark, Rockett et al. 
1991). However, recent clinical and experimental studies in CM have failed to support this 
belief (Lopansri, Anstey et al. 2003; Gramaglia, Sobolewski et al. 2006; Weinberg, Lopansri et 
al. 2008). Indeed, they did find good evidence for the protective role of NO in human CM 
(Lopansri, Anstey et al. 2003; Gramaglia, Sobolewski et al. 2006; Weinberg, Lopansri et al. 
2008). Some investigators proposed that severe malaria is associated with reduced NO 
production and low blood levels of L-arginine, the substrate for NO synthase (Yeo, 
Rooslamiati et al. 2008). Cell-free hemoglobin produced by hemolysis in falciparum malaria 
quench NO, disrupt endothelial function, increase adhesion receptor expression and impair 
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tissue perfusion (Yeo, Lampah et al. 2009). Adjunctive agents to improve endothelial NO 
bioavailability including L-arginine are being extensively tested in human patients (Yeo, 
Lampah et al. 2007; Yeo, Lampah et al. 2008; Yeo, Rooslamiati et al. 2008; Yeo, Lampah et al. 
2009) and a safety pharmacokinetics profile has been established (Yeo, Rooslamiati et al. 2008).  
5.1.3.3 Coagulation and CM 
The role of coagulation cascade in CM is controversial. However, most investigators 
propose that P. falciparum infection is associated with a procoagulant state (Francischetti 
2008). Francischetti et al proved that the coagulation cascade played a crucial role in the 
pathogenetic processes leading to the cerebral complications (Francischetti 2008). Tissue 
factor expression in the endothelium, and the amplification of the coagulation cascade by 
pRBCs and platelets at sequestration sites, contribute critically in initiating and maintaining 
a coagulation–inflammation cycle which leads to cerebral involvement in falciparum malaria 
(Francischetti 2008). In addition to the typical role in the regulation of hemostasis, 
coagulation factors have an inflammatory role [having cross talk with inflammatory 
cytokines (Esmon, Taylor et al. 1991) that is important in the pathogenesis of CM (Moxon, 
Heyderman et al. 2009)]. This finding sheds new insight into potentially novel therapies for 
CM. The possible pivotal role of platelets was reported recently from Malawian patients 
with cerebral malaria [(Wassmer, Taylor et al. 2008), see 4.4 Platelets]. Pantethine 
interrupted the early stages of the coagulation-inflammation cascade and prevented the 
cerebral syndrome in ECM model (Penet, Abou-Hamdan et al. 2008).  
5.2 Gene-expression profiling and CM 
 cDNA microarray analysis from brain tissue performed in genetically resistant (CM-R) and 
susceptible (CM-S) mice identified 327 genes discriminated between infection stages, mouse 
strains and CM-R and CM-S phenotypes (Delahaye, Coltel et al. 2006; Delahaye, Coltel et al. 
2007). Analysis of these 327 genes using expression analysis systematic explorer (EASE) 
software revealed that the clustered genes were biologically relevant to the defense response 
such as the response to malaria, inflammatory and immune response, and metabolism like 
oxidative phosphorylation, glycolysis/gluconeogenesis or tryptophan metabolism. The 
promising areas explored by this analysis shed new light on the key events that control CM 
pathogenesis and the development of therapeutic strategies. The host transcriptome 
database changed during pathogenesis of ECM in whole blood (Oakley, Anantharaman et 
al. 2011). They found over 300 potential biomarkers of ECM detectable in the circulating 
system by comparing CM-resistant BALB/c mice to those of susceptible C57BL/6 and 
CBA/Caj mice. Among these, some molecules such as complement component C1q, 
nonspecific cytotoxic cell receptor protein 1, and prostate stem cell antigen will probably be 
the main markers related to CM encephalopathy. 
5.3 Genetic polymorphisms associated with severe malaria 
5.3.1 Common erythrocyte variants and severe malaria 
Epidemiological studies in humans and experimental animals have demonstrated that 
genetic factors are very important in the initiation, progression and development of disease 
severity as well as the clinical outcome of malaria. Erythrocyte polymorphisms (variants) 
are biologically relevant to malaria pathogenesis (Min-Oo and Gros 2005). The protective 
roles of erythrocyte variants are shown in Table 1. 
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Hb variant Type of 
studies 
Function Mechanism Reference 
HbS In vivo case 
control 
Protection: CM, 
severe anemia, 
respiratory distress, 
hyperparasitemia, 
prostration, acidosis, 
and hyperlactatemia 
N/A (May, Evans et 
al. 2007) 
 In vivo mouse 
model C57 
BL/6 
Protection: ECM HO-1 activation 
via Nrf2, and 
inhibition of CD8+ 
(Ferreira, 
Marguti et al. 
2011) 
HbC In vivo case 
control 
Protection: CM, 
severe anemia 
 (Mockenhaupt, 
Ehrhardt et al. 
2004; May, Evans 
et al. 2007) 
HbF In vitro 
HMVEC cell 
culture 
Protection: malaria Impairs 
cytoadherence of 
pRBCs with EC 
and monocytes  
(Amaratunga, 
Lopera-Mesa et 
al. 2011) 
G6PD 
deficiency 
In vivo case-
control  
Protection: severe 
malaria 
N/A (Guindo, 
Fairhurst et al. 
2007) 
 In vitro 
culture of P 
falciparum 
Protection: malaria Inhibits parasite 
growth under 
oxidative stress 
and susceptibility 
to phagocytosis 
(Roth, Raventos-
Suarez et al. 1983; 
Cappadoro, 
Giribaldi et al. 
1998) 
ǂ-thalassaemia In vivo case-
control  
Reduces the risk of 
severe malaria 
Reduces 
multiplication of 
parasites 
(Mockenhaupt, 
Ehrhardt et al. 
2004) 
ǃ-thalassaemia In vitro 
culture of P 
falciparum 
Reduces the risk of 
severe malaria 
Enhances 
susceptibility of 
pRBCs to 
phagocytosis 
(Ayi, Turrini et 
al. 2004) 
(PK) deficiency In vivo mouse 
model, C57BL 
/6J, A/J, C3H 
and SJL  
Protection: malaria Enhances 
susceptibility of 
pRBCs to 
phagocytosis 
(Min-Oo, Fortin 
et al. 2003) 
Table 1. Common erythrocyte variants and severe malaria 
5.3.2 Polymorphisms of the histocompatibility region (HLA) 
T-cell recognition of malaria epitopes on infected host cells through class I and II major 
histocompatibility complex (MHC) antigens is a basic feature of pre-erythrocytic immunity 
to P. falciparum malaria. Therefore high-resolution typing of HLA class I and II loci were 
performed (Hananantachai, Patarapotikul et al. 2005; Lyke, Fernandez-Vina et al. 2011) to 
test for associations of human leukocyte antigen (HLA) alleles with malaria severity. HLA-A 
and HLA-B, DRB1 were identified as potential susceptibility factors for CM, thus providing 
further evidence that polymorphism of MHC genes results in altered malaria susceptibility. 
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6. Diagnosis, prognosis and prediction of CM encephalopathy 
WHO proposed a definition of CM as a clinical syndrome characterized by coma (inability 
to localize a painful stimulus) at least 1 h after termination of a seizure or correction of 
hypoglycaemia, detection of asexual forms of P falciparum malaria parasites on peripheral 
blood smears, and exclusion of other causes of encephalopathy (Idro, Jenkins et al. 2005; 
WHO, 2000). This definition lacks specificity, and individuals with other underlying causes 
of coma might be misdiagnosed as CM. The presence of malarial retinopathy is therefore 
recommended to differentiate patients whose comas are caused by P. falciparum or other 
reasons (See 2.2 Retinal changes associated with CM). MRI may help in the early diagnosis 
of CM so that early treatment can begin and improve the clinical outcome (Vyas, Gupta et 
al. 2010; Rasalkar, Paunipagar et al. 2011). Due to unreliable local electricity production, 
operation of MRI was always interrupted and it might take longer for MRI to become a 
regular diagnostic technique for malaria in Sub-Saharan Africa where most of CM in 
children occur. This is the major reason why an NIH-supported project of clinical 
characterization of pediatric patients with CM using neurological MRI methods in Blantyre, 
Malaŵi was not successful (Latourette, Siebert et al. 2010). More practically, the histidine-
rich protein II (HRP2)-based rapid diagnostic tests has shown high sensitivity compared to 
conventional microscopy in diagnosis of malaria and therefore may be a suitable screening 
method for malaria infection (Wilson, Adjei et al. 2008; Batwala, Magnussen et al. 2010).  
Clinical scores to predict fatal outcome in severe malaria have been developed previously 
(Helbok, Kendjo et al. 2009). A recent study in Ghanaian patients demonstrated an 
association between fatal CM and increased serum and CSF levels of proinflammatory and 
proapoptotic factors including CXCL10, IL-1ra, sTNFR1, sTNFR2, sFas and decreased serum 
and CSF levels of neuroprotective angiogenic growth factors (PDGFbb) (Armah, Wilson et 
al. 2007). Further investigations in Indian patients confirmed findings from Ghana, 
indicating that CXCL10, sTNFR2 and sFas are positively correlated, VEGF is negatively 
correlated with mortality associated with CM (Jain, Armah et al. 2008). Most recently, a 
retrospective case-control study performed by Erdman et al (Erdman, Dhabangi et al. 2011) 
indicated that host soluble triggering receptor expressed on myeloid cells-1(TREM-1) and 
soluble FMS-like tyrosine kinase-1 (Flt-1) as the biomarkers of pediatric severe and fatal 
malaria. In addition, simple biomarker combinations, such as Ang-2+procalcitonin 
(PCT)+sICAM-1, Ang-2+CXCL10+PCT, and PCT+CXCL10+sTREM could accurately predict 
death in an African pediatric population. These results suggest the utility of combinatorial 
biomarker strategies as prognostics methods to assess malaria severity (Erdman, Dhabangi 
et al. 2011). 
7. New therapies for CM 
7.1 New treatment or management of cerebral malaria 
Because of its effectiveness and cost, chloroquine has been the best and widely used antimalaria 
drug. Unfortunately P. falciparum parasite resistance to chloroquine has been observed in most 
of malaria-endemic areas (Chinappi, Via et al. 2010). The current recommended new therapies 
for CM are described in Table 2. These studies on new drugs against CM encephalopathy target 
not only parasites but the secondary damage induced by parasitemia. 
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Type of 
compound 
Type of studies  Biological effects reported Reference 
1. Anti-plasmodial drugs 
Artemisinin ICR or C57BL/6 mice 
infected by 
Plasmodium berghei 
ANKA (PbA). 
In vivo Anti-plasmodial activity; 
disruption of CD4+ and CD8+ T 
cell inflammatory responses, and 
VEGF action 
(Waknine-
Grinberg, 
Hunt et al. 
2010) 
Curcumin ICR or C57BL/6 mice 
infected by PbA. 
In vivo Anti-inflammatory properties and 
anti-plasmodial activity; inhibition 
of activity of NF-κB, production of 
NO and iNOS expression 
(Waknine-
Grinberg, 
McQuillan 
et al. 2010) 
2. Immunomodulator therapies 
Fasudil (HA-
1077) 
Primary human lung 
endothelial cells 
(HLECs) infected 
with P.falciparum 
In vitro A Rho kinase inhibitor, decreases 
both NF-kappaB activation and 
endothelial cell apoptosis 
(Taoufiq, 
Gay et al. 
2008) 
 Children infected 
with P.falciparum 
In vivo Prevents endothelium apoptosis (Zang-
Edou, 
Bisvigou 
et al. 2010), 
 ICR or C57BL/6 mice 
infected with PbA 
(both mouse strains 
serve as murine 
models for CM) 
In vivo Does not reduce parasitemia, but 
increases survival, delays or 
prevents the development of CM 
(Waknine-
Grinberg, 
McQuillan 
et al. 2010) 
E6446 Human PBMCs and 
BALB/c mouse 
spleen cells 
In vitro A synthetic antagonist of nucleic 
acid-sensing TLRs,Low doses of 
E6446 specifically inhibits the 
activation of human and mouse 
TLR9, high doses inhibits the 
human TLR8 response to single-
stranded RNA 
(Franklin, 
Ishizaka et 
al. 2011) 
 C57 BL/6 mice 
infected with 
P.berghei iRBCs 
In vivo Reduces the activation of TLR9 
and modulates cytokine response 
during acute Plasmodium 
infection, prevents limb paralysis, 
cerebral vascular leak, and death, 
(Franklin, 
Ishizaka et 
al. 2011) 
rHuEpo African children In vivo Prevents brain damage (Casals-
Pascual, 
Idro et al. 
2008) 
 C57 BL6 and CBA/J 
mice infected with 
PbA 
In vitro Epo decreases inflammatory 
response and neuronal apoptosis 
in the brain, increases survival, 
shortens coma recovery times 
(Kaiser, 
Texier et 
al. 2006; 
Bienvenu, 
Ferrandiz 
et al. 2008; 
Wiese, 
Hempel et 
al. 2008) 
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Hydroxyurea HLECs infected by 
the P.falciparum 3D7 
clone in vitro 
In vitro Up regulates ICAM-1 and 
enhances cytoadherence, but does 
not induce endothelial cell 
apoptosis. In contrast, it inhibits 
parasite growth and prevents 
mice from developing 
neurological syndrome 
(Pino, 
Taoufiq et 
al. 2006) 
Statins Simva
statin 
C57 BL6 and CBA/J 
mice infected with 
PbA 
In vivo Failes to extend survival or 
reduce parasitemia in C57BL/6 
mice infected with PbA. 
(Helmers, 
Gowda et 
al. 2009) 
EAE in C57BL/6 
mice 
In vitro Simvastatin potentiates 
production of TNF and IL-6 in 
vitro murine peritoneal 
macrophages treated with PfGPI 
(Helmers, 
Gowda et 
al. 2009) 
AVA P. falciparum cultures 
treated by AVA 
In vitro Atrovastatin (AVA) reduces the 
growth of P.falciparum in vitro 
(Parquet, 
Briolant et 
al. 2009) 
Pantethine C57 BL6 and CBA/J 
mice infected with 
PbA 
In vivo Reduces the platelet response to 
activation by thrombin and 
collagen, microparticle release by 
TNF-activated endothelial cells 
and protects against the cerebral 
syndrome 
(Penet, 
Abou-
Hamdan 
et al. 2008) 
LMP-420 HBVEC 
 
In vitro 
 
Inhibits endothelial cell 
activation, i.e., the up regulation 
of ICAM-1 and VCAM-1 on 
HBEC, abolishes the 
cytoadherence of ICAM-1-specific 
P. falciparum-parasitized RBCs on 
ECs, causes a dramatic reduction 
of HBEC microparticle release 
induced by TNF or LT 
stimulation 
(Wassmer, 
Cianciolo 
et al. 2005) 
 
N-
acetylcysteine 
amid (AD4) 
Case control In vivo Has no effect on outcomes such as 
mortality, lactate clearance or 
coma recovery times 
(Agbenye
ga, 
Planche et 
al. 2003; 
Charunwa
tthana, 
Abul Faiz 
et al. 2009) 
Levamisole Case control In vivo Decreases sequestration of pRBCs 
via inhibition of binding of 
pRBCs to CD36 
(Dondorp, 
Silamut et 
al. 2007) 
Table 2. New treatment or management of cerebral malaria 
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7.2 Malaria vaccines and CM encephalopathy 
Malaria vaccine is urgently needed to sustain the gains of malaria control. A clinical trial ( 
ClinicalTrials.gov number, NCT00380393.) on 894 children conducted in Kenya and 
Tanzania (Bejon, Cook et al. 2011) demonstrated that RTS,S/AS01E is a very promising 
malaria vaccine. RTS,S is a circumspozoite protein [CSP repeat region (R)] that targets the 
pre-erythrocytic cycle of P. falciparum in humans (Lusingu, Olotu et al. 2010; Bejon, Cook et 
al. 2011; Olotu, Lusingu et al. 2011)]. RTS,S-containing vaccines induce pre-erythrocytic 
immunity, differing from naturally acquired immunity, which largely targets blood-stage 
parasites (Bejon, Cook et al. 2011; Olotu, Lusingu et al. 2011). RTS,S/AS01E vaccines 
decrease the concentrations of antibodies to merozoite antigens, which probably reflects 
reduced exposure to blood-stage infections. Long-term protective efficacy of RTS,S 
vaccination is more likely to have a direct effect of the pre erythrocytic immunity induced 
by the vaccine, rather than the result of enhanced acquisition of immunity to blood-stage 
antigens (Bejon, Cook et al. 2011; Olotu, Lusingu et al. 2011). Although these antibodies 
were not correlated to clinical immunity, the overall effect of RTS,S vaccines still had a 
significantly lower incidence of clinical malaria than did unvaccinated individuals. 
Protection was sustained for at least 15 months (Bejon, Cook et al. 2011). Whole-parasite 
vaccine strategies (Coban, Igari et al. 2010; Coban, Yagi et al. 2010; Taylor-Robinson 2010) for 
malaria infection have attracted researchers’ attention. They trigger parasite antigen-specific 
immune responses through TLR9 and NOD-like receptors (NLRs) (Coban, Igari et al. 2010; 
Coban, Yagi et al. 2010). Heme-detoxification byproduct, hemozoin, is also being considered 
as a potential vaccine adjuvant against malaria (Coban, Igari et al. 2010; Coban, Yagi et al. 
2010). 
8. Conclusions  
A severe complication of Plasmodium infection is cerebral malaria, a condition mainly 
attributed to sequestration of pRBCs, leukocytes and platelets in cerebral microcirculation 
and overwhelming inflammatory immune reactions of the host. CM presents as a diffuse 
encephalopathy caused by P. falciparum and remains a major cause of death and disability. 
Much effort is still needed to understand the pathophysiology of this disease at the cellular 
and molecular level, to enable the development of more effective therapies aimed at both 
eliminating parasites as well as the secondary effects they cause. 
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